Therapeutic anticancer antibodies

Bibliography

• EHRLICH P: On immunity with special reference to cell life. Proc. Roy Soc. Lond. (1900) 66:424.
   Google Scholar
• JERNE NK: The natural selection theory of antibody formation. Proc. Nat. Acad. Sci. USA (1955) 41:849.
   PubMed Web of Science ®Google Scholar
• BURNET FM: A modification of Jurne's theory of antibody production using the concept of clonal selection. Aust.' Sci. (1957) 20:67.
   Google Scholar
• POTTER M: Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev (1972) 52:631.
   PubMed Web of Science ®Google Scholar
• KRAUSE RM: The search for antibodies with molecular uniformity. Adv. Immunol (1970) 12:1.
   PubMedGoogle Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells producing antibodies of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• HIMMELWEIT F (Ed.): The collected papers of Paul Ehrlich. Immunology and Cancer Res. (Vol. 4, Pergamon Press, London (1957).
   Google Scholar
• PRESSMAN D, KORNGOLD L: The in vivo localisation of anti-Wagner-osteogenic-sarcoma antibodies. (1953) Cancer 6:619.
   Google Scholar
• BALE WE SPARL F, GOODLAND RL, WOLFE DE: In vivo and in vitro studies of labelled antibodies against rat kidney and Walker carcinoma. Proc. Soc. Exp. Biol. Med. (1955) 89:564–568.
   PubMedGoogle Scholar
• QUINONES J, MIZEJEWSKI G, BEIERWALTES WH: Choriocarcinoma scanning using radiolabelled antibody to chorionic gonadotrophin. I Nuc. Med (1971) 12:69–75.
   PubMedGoogle Scholar
• MACH JP, CARREL S, MERENDA C, SORDAT B, CEROTTINI JC: In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature (1974) 248:704–706.
   PubMed Web of Science ®Google Scholar
• DYKES PW, HINE KR, BRAD WELL AR et al.: Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen. Br. Med. .1. (1980) 1:220.
   Google Scholar
• BEGENT RHJ, SEARLE F, STANWAY G et al.: Radioimmunolocalization of tumours by external scintigraphy after administration of 131 I antibody to human chorionic gonadotropin: preliminary communication. J. R. Soc. Med. (1980) 73:624.
   PubMedGoogle Scholar
• BOMANJI J, HUNGERFORD JL, GRANOWSKA M, BRITTON KE: Radioimmunoscintigraphy of ocular melanoma with Tc-99m labelled cutaneous melanoma antibody fragments. Br. J. Ophthalinol (1987) 71:651.
   PubMedGoogle Scholar
• BAUM RP, BOECKMANN W SCHULDES H et al.: In-111 anti-CEA monoclaonal antibody SPECT imaging for the identification of lymph node metastases of bladder carcinoma. Eur J. Nucl. Med. (1990) 16:417.
   Google Scholar
• EPENETOS AA, SNOOK D, HOOKER G et al.: 111Indium labelled monoclonal antibody to placental alkaline phosphatase in the detection of neoplasms of testis, ovary, and cervix. Lancet (1985) 350.
   PubMedGoogle Scholar
• BUCHEGGER F, HASKELL CM, SCHREYER M et al.: Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J. Exp. Med. (1983) 158:413.
   PubMed Web of Science ®Google Scholar
• WAHL RL, PARKER CW, PHILPOTT G: Improved radio-imaging and tumour localisation with monoclonal F(ab') 2. J. Nucl. Med. (1983) 24:316.
   PubMed Web of Science ®Google Scholar
• GERRETSEN M, QUAK JJ, SUH JS et aL: Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab') 2 fragment in xenografts of human squamous cell carcinoma of the head and neck and the vulva as compared to monoclonal antibody E48 IgG. Br. J. Cancer (1991) 63:37–44.
   PubMedGoogle Scholar
• SICCARDI AG, BURAGGI GL, CALLEGARO L et al.: Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab% fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res. (1989) 49:3095–3105.
   PubMed Web of Science ®Google Scholar
• DELALOYE B, BISCHOFF- DELALOYE A, BUCHEGGER F et al.: Detection of colorectal carcinoma by emission computerised tomography after injection of 123I-labelled Fab and F(ab')2 fragments from monoclonal anti-carcinembryonic antigen antibodies. J. Gun. Invest. (1986) 7:301–306.
   Google Scholar
• DURBIN H, MILLIGAN EM, MATHER S, TUCKER DF, RAYMOND R, BODMER W: Monoclonal antibodies to placental alkaline phosphatase: preclinical evaluation in a human xenograft tumour model of Rab') 2 and Fab fragments. hat. J. Cancer (1988) 42\(Suppl. 2):59–66.
   Google Scholar
• LARSON SM, CARRASQUILLO JA, REYNOLDS JC et al.: Therapeutic applications of radiolabelled antibodies: current situation and prospects Nucl. Med. Biol. (1986) 13:207.
   Google Scholar
• GIVOL D: The minimal antigen-binding fragment of antibodies-Fv fragment. Mol brununol (1991) 28:1379–1386.
   Google Scholar
• PLUCKTHUN A: Antibody engineering: advances in the use of Escherichia coil expression systems. Biotechnology (1991) 9:545–551.
   PubMedGoogle Scholar
• HERICOURT J, RICHET C: (1895) 120:948–952.
   Google Scholar
• BOERI DG: (1901) 6:73.
   Google Scholar
• MURRAY G: Experiments in immunity in cancer. Can. Med. Ass. .1. (1958) 79:249–259.
   PubMedGoogle Scholar
• BUINAUSKAS P, MCCREDIE JA, BROWN ER, COLE WH: Arch. Surg. Chicargo (1959) 79:432–437.
   PubMedGoogle Scholar
• SUMMER WC, FORAKER AG: Cancer (1960) 13:79–81.
   PubMedGoogle Scholar
• LASZLO J, BUCKLEY CE, AMOS CB: Infusion of isologous immune plasma in chronic lymphocytic leukemia. Blood (1968) 31:104–110.
   PubMedGoogle Scholar
• HELLSTROM I, HELLSTROM KE. Cell-mediated reactivity to human tumour-type associated antigens: does it exist? J. Biol. Response Mod (1983) 2:310–320.
   PubMedGoogle Scholar
• KUNKEL HG, MANNIK M, WILLIAMS RC: Individual antigenic specificity of isolated antibodies. Science (1963) 140:1218–1220.
   PubMed Web of Science ®Google Scholar
• GEHA RS: Regulation of the immune response by idiotype anti-idiotype interaction. New Engl. J. Med (1981) 305:25–35.
   PubMedGoogle Scholar
• TSUJISAKI M, IMAI K, TOKUCHI S et al: Induction of antigen-specific immune response with the use of anti-idiotypic monoclonal antibodies to anti-carcinoembryonic antigen antibodies. Cancer Res. (1991) 51:2599–2604.
   PubMed Web of Science ®Google Scholar
• BROWN SL, MILLER RA, HORNING SJ et al.: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with a interferon. Blood (1989) 73:651–661.
   PubMed Web of Science ®Google Scholar
• PRESSMEN D, KEIGHLEY G: I brununol (1948) 59:141–146.
   Google Scholar
• BEIERWALTERSWH: M Mich. Med. Bull (1956) 20:284.
   Google Scholar
• RAINSBURY RN, WESTWOOD JH: Tumor localisation with monoclonal antibody radioactively labeled with metal chelate rather than iodine. Lancet (1982) 12:1347.
   Google Scholar
• VRIESENDORP HM, HERPST JM, GERMACK MA et al.: Phase I-II studies of yttrium-labeled anti ferritin treatment for end-stage Hodgkin's disease including Radiation Therapy Oncology Group. I Clin. Oncol (1991) 9:918–928.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, FIG LM, ZASANDY KR et al.: Imaging, dosimetry and radioimmunotherapy with iodine 131-labelled anti-CD37 antibody in B-cell lymphoma. I Gin. Oncol (1992) 10:1696–1711.
   Google Scholar
• PRESS OW, EARY JF, APPELBAUM FR et al.: Radiolabeled-antibody therapy of B cell lymphoma with autologous bone marrow support. New Engl. J. Med (1993) 325:1219–1224.
   Google Scholar
• PIMM MV, ROBIN RA, EMBLETON MJ et al.: A bispecific monoclonal antibody against methotrexate and a human tumour-associated antigen augments cytotoxicity of methotrexate-carrier conjugate. Br. .1. Cancer (1990) 61:508–513.
   Google Scholar
• SIEVERS EL: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin. Biol .Thei: (2001) 1:893–901.
   Google Scholar
• WALDMANN TA: Monoclonal antibodiesin diagnosis and therapy. Science (1991) 252:1657–1662.
   PubMed Web of Science ®Google Scholar
• EMBLETON MJ, CHARLEWSTON A, ROBINS RA, PIMM MV, BALDWIN RW: Recombinant ricin A chain cytotoxicity against carcinoembryonic antigen-expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin B chain. Br.! Cancer (1991) 63:670–674.
   PubMedGoogle Scholar
• SPOONER RA, LORD JM: Expression ofantibody-ricin A chain fusion in mammalian cells. In: Monoclonal antibodies: applications in clinical oncology Epenetos AA (Ed.), Chapman and Hall medical, London (1991):65–77.
   Google Scholar
• PASTAN I, CHAUDHARY V, FITZGERALD DJ: Recombinant toxins as novel therapeutic agents. Ann. Rev Biochem (1992) 61:331–354.
   PubMed Web of Science ®Google Scholar
• RYBAK SM, SAXENA SK, ACKERMAN EJ, YOULE RJ: Cytotoxic potential of ribonuclease hybrid proteins. Biol. Chem (1991) 226:21202–21207.
   Google Scholar
• LINARDOU H, DEONARAIN MP, SPOONER RA, EPENETOS AA. Deoxyribonuclease I (DNAseI). A novel approach for targeted cancer therapy. Cell Biophys. (1994) 24–25:243–248.
   Google Scholar
• SOLER-RODRIGUEZ AM, GHETIE MA, OPPENHEIMER-MARKS N, URH JW, VITETTA ES: Ricin A-chain and ricin A-chain immunotwdns rapidly damage human endothelial cells: implications of vascular leak syndrome. Exp. Cell. Res (1993) 206:227–234.
   PubMed Web of Science ®Google Scholar
• GOULD BJ, BOROWITZ MJ, GROVES ES et al.: Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. Natl Cancer Inst. (1989) 81:775–781.
   Google Scholar
• FITZGERALD D, PASTAN I: Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst (1989) 81:1455–1463.
   PubMed Web of Science ®Google Scholar
• SPITLER LE, DELRIO M, KHENTIGAN A et al.: Therapy of patients with malignant-melanoma using a monoclonal antimelanoma antibody-ricin a chain immunotwdn. Cancer Res. (1987) 47:1717–1723.
   PubMed Web of Science ®Google Scholar
• SPOONER RA, MURRAY S, ROWLINSON-BUSZA G, DEONARAIN MP, CHU AC, EPENETOS AA: Genetically engineered antibodies for diagnostic pathology. Hum. Pathol (1994) 25:606–614.
   PubMedGoogle Scholar
• YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1992) 52:3402–3408.
   PubMed Web of Science ®Google Scholar
• SKERRA A, PLUCKTHUN A: Assembly ofa functional immunoglobulin Fv fragment in Escherichia coll. Science (1988) 240:1038–1040.
   PubMed Web of Science ®Google Scholar
• WARD ES, GUSSOW D, GRIFFITHS AD et al.: Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coil. Nature (1989) 341:544–546.
   PubMed Web of Science ®Google Scholar
• HUSTON JS, LEVINSON D, MUDGETT-HUNTER M et al.: Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E colt Proc Natl. Acad. Sci. USA (1988) 85:5879–5883.
   PubMed Web of Science ®Google Scholar
• BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single chain antigen-binding proteins. Science (1988) 242:423–426.
   PubMed Web of Science ®Google Scholar
• HOO WFS, LACY MJ, DENZIN LK et al.: Characterisation of a single chain T-cell receptor expressed in E. coli Proc. Natl. Acad. Sci. USA. (1992) 89:4759–4763.
   PubMedGoogle Scholar
• EPPS LA, SUN L, ARE VALO M et al.: Technetium (Tc-99m) labelled genetically engineered chimeric 17-1A G4K/ Metallothionein antibody. Nucl. Med. (1989) 30:794.
   Google Scholar
• NEDELMAN MA, SHEALY DJ, BOUTIN R et al: Rapid infarct imaging with a 99mTc antimyosin scFv fragment: Evaluation in a canine model of acute myocardial infarction. Nuclear Med. (1993) 34(2):234–241.
   PubMed Web of Science ®Google Scholar
• SEETHARAM S, CHAUDHARY VK, FITZGERALD DJ, PASTAN I: Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. (1991) 266:17376–17381.
   PubMed Web of Science ®Google Scholar
• HUSTON JS, TAI MS, MUD GETT-HUNTERM et al.: Protein Engineering of single-chain Fv analogues and fusion proteins. In: Molecular design and modeling: concepts and applications, part B. Methods in Enzymology Langone If (Ed.), (1991) 203:46–88.
   PubMed Web of Science ®Google Scholar
• DUCHOSAL MA, EMING SA, FISCHER P et al.: Immunization of hu-PBL-SCID mice and rescue of human monoclonal Fab fragments through combinatorial libraries. Nature (1992) 355:258–262.
   PubMed Web of Science ®Google Scholar
• RICHARDS J, AUGER J, PEACE D et al.:Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res. (1999) 59:2096–2101.
   PubMed Web of Science ®Google Scholar
• KIPRIYANOV SM, COCHLOVIUS B, SCHAFER HJ et al: Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. I Immunol (2002). 169:137–144.
   PubMed Web of Science ®Google Scholar
• COCHLOVIUS B, KIPRIYANOV SM, STASSAR MJ et al.: Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res. (2000) 60:4336–4341.
   PubMed Web of Science ®Google Scholar
• KODAMA H, SUZUKI M, KATAYOSE Y et al.: Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol Lett. (2002) 81:99–106.
   PubMed Web of Science ®Google Scholar
• RENNER C, PFREUNDSCHUH M: Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies. I Hematother. (1995) 4:447–451.
   PubMedGoogle Scholar
• OHMI Y, SHIKU H, NISHIMURA T: Tumor-specific targeting of T helper Type 1 (Thl) cells by anti-CD3 x anti-c-ErbB-2 bispecific antibody. Cancer Immunol Immunother. (1999) 48:456–462.
   PubMedGoogle Scholar
• LUM LG, SEN M: Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside. Acta Haematol (2001) 105: 130–136.
   PubMed Web of Science ®Google Scholar
• ZHU Z, LEWIS GD, CARTER P: Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells. Int. I Cancer (1995) 62:319–324.
   PubMed Web of Science ®Google Scholar
• JUNG G, BRANDL M, EISNER W et al:Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int. Cancer (2001) 91:225–230.
   PubMed Web of Science ®Google Scholar
• RICE DC, CHAPOVAL Al, PORTER L, NELSON H: Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody. Cancer Immunol Immunother. (1999) 48:230–238.
   PubMedGoogle Scholar
• DAVICO BONINO L, DE MONTE LB, SPAGNOLI GC et al.: Bispecific monoclonal antibody anti-CD3 x anti-tenascin: an immunotherapeutic agent for human glioma. Intl Cancer (1995) 61: 509–515.
   PubMedGoogle Scholar
• BERNHARD H, KARBACH J, STRITTMATTER W, MEYER ZUM BUSCHENFELDE KH, KNUTH A: Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. hat. I Cancer (1993) 55:465–470.
   PubMedGoogle Scholar
• HOMBACH A, TILLMANN T, JENSEN M et al.: Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/ CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. bninunother (1997) 20:325-333. ao.SHEN GL, LI JL, VITETTA ES: Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. brimunol. (1994) 152:2368–2376.
   Google Scholar
• LIAO KW, LO YC, ROFFLER SR: Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. (2000) 7:339–347.
   PubMedGoogle Scholar
• FOSS FM, RAUBITSCHECK A, MULSHINE JL et al.: Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin. Cancer Res (1998) 4:2691–2700.
   PubMed Web of Science ®Google Scholar
• ZIMMER AM, ROSEN ST, SPIES SM et al.: Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-1-31-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. Nucl. Med. (1988) 29:174–180.
   Google Scholar
• RAVEL S, COLOMBATTI M, CASELLAS P: Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells. Blood (1992) 79:1511–1517.
   PubMedGoogle Scholar
• HERTLER AA, SCHLOSSMAN DM, BOROWITZ MJ, BLYTHMAN HE, CASELLAS P, FRANKEL AE: An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. hat. J. Cancer (1989) 43: 215–219.
   PubMed Web of Science ®Google Scholar
• RAVEL S, CASELLAS P: Internalization of the cytotoxic molecules of T101 F (ab')2- (ricin-A-chain) immunotoxin into human T-leukemic cells. Ear Biochem. (1990) 192:469–473.
   PubMedGoogle Scholar
• MA D, MCDEVITT MR, BARENDSWAARD E et al.: Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia (2002) 16: 60–66.
   PubMed Web of Science ®Google Scholar
• IDEN DL, ALLEN TM: In vitro and M vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim. Biophys. Acta. (2001) 1513:207–216.
   PubMed Web of Science ®Google Scholar
• EK O, GAYNON P, ZEREN T, CHELSTROM LM, MYERS DE, UCKUN FM: Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase. Leak. Lymphoma (1998) 31:143–149.
   PubMed Web of Science ®Google Scholar
• MYERS DE, SICHENEDER A, CLEMENTSON D et al.: Large scale manufacturing of B43 (anti- CD 19) - genistein for clinical trials in leukemia and lymphoma. Leak. Lymphoma (1998) 29:329–338.
   PubMed Web of Science ®Google Scholar
• FLAVELL DJ, NOSS A, PULFORD KA,LING N, FLAVELL SU: Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. (1997) Cancer Res. 57: 4824–4829.
   Google Scholar
• FLAVELL DJ, BOEHM DA, EMERY L, NOSS A, RAMSAY A, FLAVELL SU: Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int. J. Cancer (1995) 62:337–344.
   PubMed Web of Science ®Google Scholar
• GHETIE MA, PODAR EM, GORDON BE, PANTAZIS P, UHR JW, VITETTA ES: Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int. J. Cancer (1996) 68:93–96.
   PubMed Web of Science ®Google Scholar
• GIDLOF C, DOHLSTEN M, LANDO P, KALLAND T, SUNDSTROM C, TOTTERMAN TH: A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Blood (1997) 89:2089–2097.
   PubMed Web of Science ®Google Scholar
• SHAH SA, HALLORAN PM, FERRIS CA et al.: Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. (1993) 53:1360–1367.
   PubMed Web of Science ®Google Scholar
• STONE MJ, SAUSVILLE EA, FAY JVV et aL:A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 88:1188–1197.
   PubMed Web of Science ®Google Scholar
• FLAVELL DJ, FLAVELL SU, BOEHM DA et al.: Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br. J. Cancer (1995) 72:1373–1379.
   PubMed Web of Science ®Google Scholar
• RHODES EG, BAKER PK, RHODES JM,DAVIES JM, DUGUID JK: Autologous bone marrow transplantation for myeloma patients using PNA- and CD19-purged marrow rescue. Bone Marrow Transplant(1994) 13:795–799.
   PubMed Web of Science ®Google Scholar
• ROWLAND AJ, PIETERSZ GA, MCKENZIE IF: Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol brimunother (1993) 37:195–202.
   PubMed Web of Science ®Google Scholar
• GUILLEM VM, TORNIO M, REVERT F et al.: Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. Gene Merl (2002) 4:170–182.
   Google Scholar
• GHETIE MA, GHETIE V, VITETTA ES: Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Chit. Cancer Res. (1999) 5:3920–3927.
   PubMed Web of Science ®Google Scholar
• COIFFIER B: Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin. Oncol (2002) 29(2 Supp1.6) :18–22.
   Google Scholar
• FRIEDBERG JVV, NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with ritwdmab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. J. Haematol (2002) 117: 828–834.
   PubMedGoogle Scholar
• KIMBY E: Beyond immunochemotherapy: combinations of ritwdmab with cytokines interferon-a2a and granulocyte-macrophage colony stimulating factor. Semin. Omni (2002) 29(2 Supp1.6):7–10.
   Google Scholar
• TREON SP, PILARSKI LM, BELCH AR et al.: CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. Immunother (2002) 25:72–81.
   PubMed Web of Science ®Google Scholar
• NABHAN C, ROSEN ST: Conceptual aspects of combining ritwdmab and Campath-1H in the treatment of chronic lymphocytic leukemia. Semin. Oncol (2002) 29(1 Supp1.2):75–80.
   Google Scholar
• ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with ritwdmab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99:67–74.
   PubMed Web of Science ®Google Scholar
• JOYCE RM, KRASER CN, TETREALT JC et al.: Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B- cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Ear. HaematoL SuppL (2001) 64:56–62.
   PubMedGoogle Scholar
• WILSON WH, GUTIERREZ M, O'CONNOR P et al.: The role of ritiiximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Seinin. Oncol (2002) 29(1 Supp1.2):41–47.
   Google Scholar
• ALAS S, BONAVIDA B, EMMANOUILIDES C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and ritiiximab. Anti-Cancer Res (2000) 20:2961–2966.
   PubMed Web of Science ®Google Scholar
• BEHR TM, GRIESINGER F, RIGGERT J et al.: High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer (2002) 94(4 Suppl.):1363–1372.
   Google Scholar
• HENDRIX CS, DE LEON C, DILLMAN RO: Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tffixetan. Clin. Oncol Nurs. (2002) 6:144–148.
   Google Scholar
• WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritiiximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol (2002) 20:3262–3269.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tffixetan radioimmunotherapy versus ritwdmab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. j. Clin. Oncol (2002) 20:2453–2463.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, ZELENETZ AD, PRESS OW et al: Pivotal study of iodine 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. Clin. Oncol (2001) 19: 3918–3928.
   Web of Science ®Google Scholar
• GOPAL AK, RAJENDRAN JG, PETERSDORF SH et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood (2002) 99:3158–3162.
   PubMed Web of Science ®Google Scholar
• KORAL KF, FRANCIS IR, KROLL S, ZASADNY KR, KAMINSKI MS, WAHL RL: Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. Cancer (2002) 94(4 Suppl.):1258–1263.
   Google Scholar
• LINDEN O, TENNVALL J, HINDORF C et al: 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol (2002) 41:297–303.
   Google Scholar
• JUWEID ME, STADTMAUER E, HADAR G et al.: Pharmacokinetics, dosimetry, and initial therapeutic results with 1311- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Cl/n. Cancer Res. (1999) 5(10 Suppl.):3292s–3303s.
   Google Scholar
• BARTH S: Technology evaluation: BL22, NCI. Curr. Opin. Mol. Ther. (2002) 4:72–75.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, WILSON WH, BERGERON K et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. (2001) 345:241–247.
   PubMed Web of Science ®Google Scholar
• NEWTON DL, RYBACK SM: Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA. Expert Opin. Biol. Ther. (2001) 1:995–1003.
   PubMed Web of Science ®Google Scholar
• NEWTON DL, HANSEN HJ, MIKULSKI SM, GOLDENBERG DM, RYBAK SM: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. B/ood(2001) 97:528–535.
   Google Scholar
• BEHR TM, WORMANN B, GRAMATZKI M et al.: Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin. Cancer Res. (1999) 5(10 Suppl.):3304s–3314s.
   Google Scholar
• FRENCH RR, PENNEY CA, BROWNING AC, STIRPE F, GEORGE AJ, GLENNIE MJ: Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br. J. Cancel: (1995) 71:986–994.
   Google Scholar
• LUNDBERG BB, GRIFFITHS G, HANSEN HJ: Specific binding of sterically stabilized anti-B Cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int. Pliarin. (2000) 205:101–108.
   Google Scholar
• TSUTSUMI Y, ONDA M, NAGATA S, LEE B, KREITMAN RJ, PASTAN I: Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Nall Acad. Sci. USA (2000) 97:8548–8553.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, WILSON WH, WHITE JD et al: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Clin. Oncol (2000) 18:1622–1636.
   Web of Science ®Google Scholar
• ROBBINS DH, MARGULIES I, STETLER-STEVENSON M, KREITMAN RJ: Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res. (2000) 6:693–700.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA, WHITE JD, CARRASQUILLO JA et al.: Radioimmunotherapy of interleukin-2R a-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 86: 4063–4075.
   PubMed Web of Science ®Google Scholar
• ZHANG M, YAO Z, GARMESTANI K et al.: Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the a-emitting radionuclide, bismuth 213. Blood (2002) 100:208–216.
   PubMed Web of Science ®Google Scholar
• ESTEY EH, THALL PF, GILES FJ et al: Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood (2002) 99: 4343–4349.
   PubMed Web of Science ®Google Scholar
• ESTEY EH, GILES FJ, BERAN M et al.: Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99:4222–4224.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, LINENBERGER M: Mylotarg: antibody-targeted chemotherapy comes of age. Carr. Opin. Oncol (2001) 13:522–527.
   PubMedGoogle Scholar
• JURCIC JG: Antibody therapy for residual disease in acute myelogenous leukemia. Crit. Rev Oncol Heinatol (2001) 38:37–45.
   PubMed Web of Science ®Google Scholar
• PAGLIARO LC, LIU B, MUNKERR et al: Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin. Cancer Res (1998) 4:1971–1976.
   PubMed Web of Science ®Google Scholar
• BALAIAN L, BALL ED: Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leak. Res (2001) 25:1115–1125.
   PubMed Web of Science ®Google Scholar
• FLAVELL DJ, BOEHM DA, NOSS A, WARNES SL, FLAVELL SU: Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br. J. Cancer. (2001) 84:571–578.
   PubMed Web of Science ®Google Scholar
• ELLIS JH, BARBER KA, "NTT A et al.: Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. Immunol (1995) 155:925–937.
   Google Scholar
• GOLDMACHER VS, BOURRET LA, LEVINE BA et al.: Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood (1994) 84:3017–3025.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL: Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother. Pharmacol (2000) 46:518–522.
   Google Scholar
• APPELBAUM FR: Antibody-targeted therapy for myeloid leukemia. Semin. Hematol (1999) 36(4 Supp1.6):2–8.
   Google Scholar
• DE KROON JF, DE PAUS RA, KLUIN-NELEMANS HC et al: Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. Exp. Hematol (1996) 24:919–926.
   PubMed Web of Science ®Google Scholar
• MATTHEWS DC, APPELBAUM FR, EARY JF et al.: Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD4 5 antibody, combined with cyclophosphamide and total body irradiation. Blood(1995) 85:1122–1131.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768–773.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-111) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554–3561.
   PubMed Web of Science ®Google Scholar
• UPPENKAMP M, ENGERT A, DIEHL V, BUNJES D, HUHN D, BRITTINGER G: Monoclonal antibody therapy with CAMPATH-111 in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter Phase I/II study. Ann. Hematol (2002) 81:26–32.
   PubMed Web of Science ®Google Scholar
• CULL GM, HAYNES AP, BYRNE JL et al.: Preliminary experience of allogeneic stem Cell Transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br. J. Haematol (2000) 108:754–760.
   PubMed Web of Science ®Google Scholar
• LEWIS LD, BEELEN AP, COLE BF et al.: The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon 7-lb in a multiple-dose Phase I study in patients with advanced cancer. Cancer Chemother. Pharmacol (2002) 49:375–384.
   PubMed Web of Science ®Google Scholar
• JAMES ND, ATHERTON PJ, JONES J, HOWIE AJ, TCHEKMEDYIAN S, CURNOW RT: A Phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HERZ advanced prostate cancer. Br. J. Cancer (2001) 85:152–156.
   PubMed Web of Science ®Google Scholar
• SUVAS S, SINGHV, SAHDEV S, VOHRA H, AGREWALA JN: Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. Biol. Chem. (2002) 277:7766–7775.
   Google Scholar
• VOOIJS WC, OTTEN HG, VAN VLIET M et al.: B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br: J. Cancer (1997) 76:1163–1169.
   Google Scholar
• SCHOPF RE: IDEC-114 (IDEC). Carr. Opin. Investig. Drugs (2001) 2:635–638.
   PubMedGoogle Scholar
• KIRCHNER EM, GERHARDS R, VOIGTMANN R: Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann. Oncol (2002) 13:1044–1048.
   PubMedGoogle Scholar
• SCHWARTZBERG LS: Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Omni Hematol (2001) 40:17–24.
   PubMed Web of Science ®Google Scholar
• NAUNDORF S, PREITHNER S, MAYER P et al.: In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int. J. Cancer (2002) 100:101–110.
   PubMed Web of Science ®Google Scholar
• BAUM RP, NIESEN A, HERTEL A et al.: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (1994) 73(3 Suppi.):1121–1125.
   Google Scholar
• SCHMOLLING J, WAGNER U, REINSBERG J, BIERSACK HJ, KREBS D: Immune reactions and survival of patients with ovarian carcinomas after administration of 1-31I-F(Ab)2 fragments of the OC 125 monoclonal antibody. Ceburtshilfe Frauenheilkd. (1995) 55:200–203.
   PubMedGoogle Scholar
• MAHE MA, FUMOLEAU P, FABBRO M et al.: A Phase II study of intraperitoneal radioimmunotherapy with iodine-131 labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. (1999) 5(10 Suppl.):3249s–3253s.
   Google Scholar
• DUSKA LR, HAMBLIN MR, MILLER JL, HASAN T: Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. I Natl. Cancer Inst. (1999) 91:1557–1563.
   PubMedGoogle Scholar
• ABE H, KUROKI M, TACHIBANA K et al.: Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anti-Cancer Res. (2002) 22:1575–1580.
   PubMed Web of Science ®Google Scholar
• SENBA T, KUROKI M, ARAKAWA F et al.: Tumor growth suppression by a mouse/ human chimeric anti-CEA antibody and lymphokine-activated killer cells M vitro and in SCID mouse xenograft model. Anti Cancer Res. (1998) 18:17–24.
   PubMedGoogle Scholar
• BEHR TM, LIERSCH T, GREINER-BECHERT L et al: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 94(4 Suppl.):1373–1381.
   Google Scholar
• STEIN R, JUWEID M, ZHANG CH, GOLDENBERG DM: Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer. Clin. Cancer Res. (1999) 5(10 Suppl.):3199s–3206s.
   Google Scholar
• JUWEID ME, HAJJAR G, SWAYNE LC et al.: Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer (1999) 85: 1828-1842.
   Google Scholar
• AKAMATSU Y, MURPHY JC, NOLAN KF et al.: A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin. Cancer Res. (1998) 4:2825–2832.
   PubMed Web of Science ®Google Scholar
• PATRICK MR, CHESTER KA, PIETERSZ GA: In vitro characterization of a recombinant 32P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody. Cancer Immunol Immunother. (1998) 46:229–237.
   Google Scholar
• YCHOU M, PELEGRIN A, FAUROUS P et al.: Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer. Int. J. Cancer (1998) 75:615–619.
   PubMed Web of Science ®Google Scholar
• XU X, CLARKE P, SZALAIG et at Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. (2000) Cancer Res. 60: 4475–4484.
   Google Scholar
• KIM JC, ROH SA, KOO KH et al: Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery. Int. J. Cancer (2002) 97:542–547.
   PubMedGoogle Scholar
• MAYER A, ISIOMPANOU E, O'MALLEY D et al.: Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res. (2000) 6:1711–1719.
   Google Scholar
• CHESTER KA, MAYER A, BHATIAJ et al.: Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. (2000) Cancer Chemother: Pharmacol 46 (Suppl.):S8–S12.
   Google Scholar
• STRIBBLING SM, MARTIN J, PEDLEY RB, BODEN JA, SHARMA SK, SPRINGER CJ: Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother. Pharmacol (1997) 40:277–284.
   PubMedGoogle Scholar
• CASEY JL, KING DJ, CHAPLIN LC et al: Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br. J. Cancer (1996) 74:1397–1405.
   PubMed Web of Science ®Google Scholar
• PEDLEY RB, BODEN JA, BODENR et al: The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. Cancer (1994) 70:1126–1130.
   Google Scholar
• MARSHALL D, PEDLEY RB, BODEN JA, BODEN R, BEGENT RH: Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model. Br. J. Cancer (1994) 69:502–507.
   PubMed Web of Science ®Google Scholar
• ROBERT B, MACH JP, MANI JC et al: Cone targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor a. Cancer Res. (1996) 56:4758–4765.
   PubMed Web of Science ®Google Scholar
• KUROKI M, ARAKAWA F, KHARE PD et al.: Specific targeting strategies of Cancer Gene Therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Anticancer Res. (2000) 20:4067–4071.
   PubMedGoogle Scholar
• KONISHI H, OCHIYA T, CHESTER KA et al.: Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum. Gene Ther. (1998) 9:235–248.
   PubMedGoogle Scholar
• FOON KA, JOHN WJ, CHAKRABORTY M et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. j. Clin. Oncol (1999) 17:2889–2895.
   PubMed Web of Science ®Google Scholar
• 112IPATHI PK, QIN H, DENG S et al: Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. MM. Immunol (1998) 35:853–863.
   Google Scholar
• SPENDLOVE L, LI L, POTTER V, CHRISTIANSEN D, LOVELAND BE, DURRANT LG: A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions. Ear: J. kimono' (2000) 30:2944–2953.
   Google Scholar
• DENTON GW, DURRANT LG, HARDCASTLE JD, AUSTIN EB, SE WELL HF, ROBINS RA: Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer (1994) 57:10–14.
   PubMed Web of Science ®Google Scholar
• MAXWELL-ARMSTRONG CA, DURRANT LG, BUCKLEY TJ et al.: Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br: J. Cancer (2001) 84:1443–1446.
   Google Scholar
• GAUTHEROT E, LE DOUSSAL JM, BOUHOU J et al.: Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. Nucl. Med. (1998) 39:1937–1943.
   Google Scholar
• NAKAKI M, TAKIKAWA H, YAMANAKA M: Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro. J. Int. Med. Res. (1997) 25:14–23.
   PubMedGoogle Scholar
• MEREDITH RF, KHAZAELI MB, PLOTT WE et al.: Phase II study of dual 131I labeledmonoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Cita Cancer Res (1996) 2: 1811-1818.
   Google Scholar
• KARASHIMA T, SWEENEY P, SLATON JW et al.: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Chit. Cancer Res. (2002) 8:1253–1264.
   PubMed Web of Science ®Google Scholar
• OVERHOLSER JP, PREWETT MC, HOOPER AT, WAKSAL HW, HICKLIN DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89:74–82.
   PubMed Web of Science ®Google Scholar
• PREWETT MC, HOOPER AT, BASSI R, ELLIS LM, WAKSAL HW, HICKLIN DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. (2002) 8:994–1003.
   PubMed Web of Science ®Google Scholar
• HERBST RS, LANGER CJ: Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol (2002) 29(1 Supp1.4):27–36.
   Google Scholar
• LYNCH DH, YANG XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol (2002) 29(1 Supp1.4):47–50.
   Google Scholar
• GONZALEZ B, CASACO A, ALVAREZ P et al. Radiotoxicity of h-R3 monoclonal antibody labeled with 188Re administered intracerebrally in rats. Hum. Exp. Toxicol (2000) 19:684–692.
   PubMedGoogle Scholar
• MORALES-MORALES A, DUCONGE J, CABALLERO-TORRES I, NUNEZ-GANDOLFF G, FERNANDEZ E, IZNAGA-ESCOBAR N: Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl. Med. Biol. (1999) 26:275–279.
   PubMedGoogle Scholar
• SOLBACH C, ROLLER M, AHR A et al: Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int. J. Cancer (2002) 101:390–394.
   PubMedGoogle Scholar
• STEINER K, HAUNSCHILD J, FARO HP, SENEKOWITSCH R: Distribution of humanized MAb 425 (EMD 62,000) in rats and specific localization in tumor-bearing nude mice. Cell. MM. Biol. (1995) 41:179–184.
   PubMedGoogle Scholar
• STRAGLIOTTO G, VEGA F, STASIECKI P, GROPP P, POISSON M, DELATTRE JY: Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur: J. Cancer (1996) 32A:636–640.
   Google Scholar
• BIER H, HOFFMANN T, HAUSER U et al: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother: Pharmacol (2001) 47:519–524.
   PubMed Web of Science ®Google Scholar
• HAMBEK M, SOLBACH C, SCHNUERCH HG et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res. (2001) 61:1045–1049.
   PubMed Web of Science ®Google Scholar
• PATRICK TA, KRANZ DM, ZACHARY JF, ROY EJ: Intracerebral bispecific ligand-antibody conjugate, increases survival of animals bearing endogenously arising brain tumors. Int. J. Cancer (1998) 78:470–479.
   PubMedGoogle Scholar
• BOERMAN OC, TIBBEN JG, MASSUGER LF, CLAESSENS RA, CORSTENS FH: Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental M0v18 antibody in experimental ovarian cancer. Anti-Cancer Res. (1995) 15:2169–2174.
   PubMedGoogle Scholar
• CRIPPA F, BOLIS G, SEREGNI E et al.: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1311- M0v18: clinical results in patients with minimal residual disease of ovarian cancer. Eur: I Cancer (1995) 31A:686–690.
   PubMed Web of Science ®Google Scholar
• ANDERSSON H, PALMS, LINDEGREN S et al.: Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody M0v18 in nude mice with intraperitoneal growth of human ovarian cancer. Anti-Cancer Res. (2001) 21:409–412.
   PubMedGoogle Scholar
• BOUABDALLAH R, OLIVE D, MEYER P et al.: Anti-GM-CSF monoclonal antibody therapy for refractory acute leukemia. Leak. Lymphoma (1998) 30:539–549.
   PubMed Web of Science ®Google Scholar
• AZZOLI CG, KRUG LM, MILLER VA, KRIS MG, MASS R: Trastuzumab in the treatment of non-small cell lung cancer. &min. Oncol (2002) 29(1 Supp1.4):59–65.
   Google Scholar
• MCKEAGE K, PERRY CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HERZ. Drugs (2002) 62:209–243.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY J, VUKELJA SJ, MARSLAND T, KIMMEL G, RATNAM S, PIPPEN J: Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin. Breast Cancer (2002) 3 (Supp1.1) :17–20.
   Google Scholar
• ESTEVA FJ, VALERO V, BOOSERD et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Clin. Omni (2002) 20:1800–1808.
   PubMed Web of Science ®Google Scholar
• MILLER KD, SISK J, ANSARIR et al: Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) (2001) 15(2 Supp1.3):38–40.
   Google Scholar
• EIERIVIANN W: International herceptin study group: Trastuzumab combined with chemotherapy for the treatment of HERZ-positive metastatic breast cancer: pivotal trial data. Ann. Oncol (2001) 12\(Supp1.1):S57–S62.
   Google Scholar
• PEGRAM MD, LOPEZ A, KONECNY G, SLAM ON DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. &min. Oncol (2000) 27(6 Supp1.11):21–25.
   Google Scholar
• MANDLER R,WU C, SAUSVILLE EA et al.: Immunoconjugates of geldanamycin and anti-HERZ monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.' Natl. Cancer hut. (2000) 92: 1573–1581.
   Google Scholar
• COLBERN GT, HILLER AJ, MUSTERER RS, WORKING PK, HENDERSON IC: Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HERZ positive human breast cancer model. J. Inorg. Biochem. (1999) 77:117–120.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, BOK R, REESE DM, SUDILOVSKY D, FROHLICH M: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. &min. Oncol (2001) 28(4 Supp1.15):71–76.
   Google Scholar
• DENARDO GL, O'DONNELL RT, ROSE LM, MIRICK GR, KROGER LA, DENARDO SJ: Milestones in the development of Lym-1 therapy. Hybridoma (1999) 18:1–11.
   PubMedGoogle Scholar
• O'DONNELL RT, SHEN S, DENARDO SJ et al.: A Phase I study of 90Y-21T-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. Anti-Cancer Res (2000) 20:3647–3655.
   Google Scholar
• O'DONNELL RT, LEIGH BR, CHRISTENSEN SD et al.: Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma. Cancer Brother. Radiopharm. (1999) 14:167–176.
   Google Scholar
• O'DONNELL RT, DENARDO GL, KUKIS DL et al: A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. Nucl. Med. (1999) 40:2014–2020.
   Google Scholar
• HU P, HORNICK JL, GLASKY MS et al: A chimeric Lym-1/interleulkin 2 fusion protein for, increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res. (1996) 56:4998–5004.
   PubMed Web of Science ®Google Scholar
• KVALHEIM G, FUNDERUD S, KVALOY S et al.: Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. NatL Cancer Inst. (1988) 80:1322–1325.
   Google Scholar
• DENARDO DG, XIONG CY, SHI XB, DENARDO GL, DENARDO SJ: Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Brother. Radiopharm. (2001) 16:525–535.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, LINK BK: Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol (2002) 29(1 Supp1.2):81–86.
   Google Scholar
• KHAWLI LA, MILLER GK, EPSTEIN AL: Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer (1994) 73(3 Suppl.):824–831.
   Google Scholar
• HORNICK JL, SHARIFI J, KHAWLI LA et al.: A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Brother: Radiopharm. (1998) 13:255–268.
   PubMed Web of Science ®Google Scholar
• SHARIFI J, KHAWLI LA, HU P, KING S, EPSTEIN AL: Characterization of a phage display-derived human monoclonal antibody (NH576) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics (2001) 20: 305–312.
   PubMedGoogle Scholar
• GHOSH S, CHAMPLIN RE, UENO NT et al.: Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant (2001) 28:271–275.
   PubMed Web of Science ®Google Scholar
• MOLICA S, MUSTO P, CHIURAZZI F et al.: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 81:121–126.
   PubMed Web of Science ®Google Scholar
• SHOENFELD Y, FISHMAN P: Gamma-globulin inhibits tumor spread in mice. Int. Immunol (1999) 11:1247–1252.
   PubMed Web of Science ®Google Scholar
• MERIMSKY O, MELLER I, INBAR M, BAR-YEHUDA S, SHOENFELD Y, FISHMAN P: A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. (2002) mt. .1 Onto' 20: 839–843.
   Google Scholar
• LINARDOU H, EPENETOS AA, DEONARAIN MP: A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. Int. J. Cancer (2000) 86:561–569.
   PubMed Web of Science ®Google Scholar
• SMANS KA, INGVARSSON MB, LINDGREN P et al.: Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens. Int. .1 Cancer (1999) 83:270–277.
   Google Scholar
• SMANS KA, HOYLAERTS MF, NARISAWA S, MILLAN JL, DE BROE ME: Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice. Cancer Res. (1995) 55:4383–4390.
   PubMedGoogle Scholar
• RIVA P, MARANGOLO M, TISON V et al.: Radioimmunotherapy trials in germ testicular carcinoma: a Phase I study. Int. .1 Biol. Markers (1990) 5:188–194.
   Google Scholar
• KALOFONOS HP, PAWLIKOWSKA TR, HEMINGWAY A et al.: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. Nucl. Med. (1989) 30:1636–1645.
   Web of Science ®Google Scholar
• AKEWANLOP C, WATANABE M, SINGH B, WALKER M, KUFE DW, HAYES DF: Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res. (2001) 61:4061–4065.
   PubMed Web of Science ®Google Scholar
• MOASE EH, QIW, ISHIDA T et al.: Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochlin. Biophys. (2001) 1510:43–55.
   PubMedGoogle Scholar
• RICHMAN CM, DENARDO SJ: Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Grit. Rev Oncol Hematol (2001) 38:25–35.
   PubMedGoogle Scholar
• SUPIOT S, FAIVRE-CHAUVET A, COUTURIER O et al.: Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labelled with iodine-131 and bismuth-213 on multiple myeloma. Cancer (2002) 94(4 Suppl.):1202–1209.
   Google Scholar
• ENGEBRAATEN O, SIVAM G, JUELL S, FODSTAD O: Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int. .1 Cancer (2000) 88:970–976.
   PubMed Web of Science ®Google Scholar
• PIETERSZ GA, VVENJUN L, KRAUER K, BAKER T, WRESCHNER D, MCKENZIE IF: Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer binnunot Inanunother. (1997) 44:323–328.
   PubMed Web of Science ®Google Scholar
• KODAMA H, SUZUKI M, KATAYOSE Y et al.: Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma. Cancer Innnunol Innnunother. (2001) 50:539–548.
   PubMed Web of Science ®Google Scholar
• EPENETOS AA, HIRD V, LAMBERT H, MASON P, COULTER C: Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int. J .Cynecol .Cancer (2000) 10:44–46.
   PubMed Web of Science ®Google Scholar
• MARAVEYAS A, STAFFORD N, ROWLINSON-BUSZA G, STEWART JS, EPENETOS AA: Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res. (1995) 55:1060–1069.
   PubMedGoogle Scholar
• LJUNG G, LENNERNAS B, NORDGREN H et al.: Human milk fat globule antigen 1 (HMFG1) expression in prostatic carcinoma and immunotargeting with a radiolabelled monoclonal anti-HMFG1 antibody. Anti-Cancer Res. (2000) 20:2321–2324.
   PubMedGoogle Scholar
• O'DONNELL RT, DENARDO SJ, YUAN A et al.: Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. (2001) 7:1561–1568.
   Google Scholar
• MCDEVITT MR, BARENDSWAARD E, MA D et al.: An a-particle emitting antibody ([213Bi]J59 for radioimmunotherapy of prostate cancer. Cancer Res. (2000) 60:6095–6100.
   PubMed Web of Science ®Google Scholar
• KAHN D, AUSTIN JC, MAGUIRE RT, MILLER SJ, GERSTBREIN J, WILLIAMS RD: A Phase II study of [9°Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother. Radiophann. (1999) 14:99–111.
   PubMedGoogle Scholar
• SINHA AA, QUAST BJ, REDDY PK, ELSON MK, WILSON MJ. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anti-Cancer Res. (1999) 19:893–902.
   Google Scholar
• SCHNEEBAUM S, TROITSA A, HADDAD R et al.: Immunoguided lymph node dissection in colorectal cancer: a new challenge? World J. Sing. (2001) 25:1495–1498.
   Google Scholar
• MCINTOSH DG, COLCHER D, SEEMAYER T, SMITH ML: The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe. Cancer Biother. Radiophann. (1997) 12:287–294.
   PubMedGoogle Scholar
• MULLIGAN T, CARRASQUILLO JA, CHUNG Y et al.: Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. (1995) 1:1447–1454.
   PubMed Web of Science ®Google Scholar
• SLOVIN SF, SCHER HI, DIVGI CR et al.: Interferon-y and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res. (1998) 4:643–651.
   PubMedGoogle Scholar
• TEMPERO M, LEICHNER P, BARANOWSKA-KORTYLEWICZ J et al.: High-dose therapy with 9°Yttrium-labeled monoclonal antibody CC49: a Phase I trial. Clin Cancer Res. (2000) 6:3095–3102.
   PubMed Web of Science ®Google Scholar
• MEREDITH RF, ALVAREZ RD, PARTRIDGE EE et al.: Intraperitoneal radioimmunochemotherapy of ovarian cancer: a Phase I study. Cancer Biotite]: Radiophann. (2001) 16:305–315.
   PubMed Web of Science ®Google Scholar
• KASHMIRI SV, IWAHASHI M, TAMURA M, PADLAN EA, MILENIC DE, SCHLOM J: Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. Grit. Rev Oncol Hematol (2001) 38:3–16.
   PubMedGoogle Scholar
• GOEL A, AUGUSTINE S, BARANOWSKA-KORTYLEWICZ J et al.: Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs. Clin. Cancer Res. (2001) 7:175–184.
   PubMed Web of Science ®Google Scholar
• GOEL A, BERESFORD GW, COLCHER D et al.: Divalent forms of CC49 single-chain antibody constructs in Pichiapastoris: expression, purification, and characterization. Biochern. (2000) 127:829–836.
   Google Scholar
• KELLY FJ, MILLER CR, BUCHSBAUM DJ et al.: Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitra Cancer Re.s (2000) 6:4323–4333.
   Google Scholar
• DOMINGO RI, REILLY RM: Pm-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 9°Y-DOTA-biotin. Nucl. Med. Commun. (2000) 21:89–96.
   PubMedGoogle Scholar
• JOHNSON DA, BRIGGS SL, GUTOWSKI MC, BARTON R: Anti-tumor activity of CC49-doxorubicin immunoconjugates. Anti-Cancer Res. (1995) 15:1387–1393.
   PubMed Web of Science ®Google Scholar
• MURRAY S, LINARDOU H: Non-cancer therapeutic antibodies. Expert Opin. Ther. Patents (2002) 12:401–417.
   Google Scholar
• TREHU EG, MIER JW, DUBOIS JS et al: Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin. Cancer Res. (1996) 2:1341–1351.
   PubMedGoogle Scholar
• COURIEL DR, HICKS K, GIRALT S, CHAIVIPLIN RE: Role of tumor necrosis factor-a inhibition with inflixiIVIAB in cancer therapy and hematopoietic stem cell transplantation. Cum Opin. Oncol. (2000) 12:582–587.
   PubMed Web of Science ®Google Scholar
• BREKKEN RA, OVERHOLSER JP, STASTNY VA, WALTENBERGER J, MINNA JD, THORPE PE: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117–5124.
   PubMed Web of Science ®Google Scholar
• SOH EY, EIGELBERGER MS, KIM KJ et a/.: Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in viva Surgery (2000) 128:1059–1065.
   Google Scholar
• HUNT S: Technology evaluation: IMC-1C11, ImClone Systems. Curr. Opin. Mol. Ther. (2001) 3:418–424.
   PubMed Web of Science ®Google Scholar
• KLEMENT G, HUANG P, MAYERB et a/.: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Gin. Cancer Res. (2002) 8:221–232.
   Google Scholar
• ZHANG L, YU D, HICKLIN DJ, HANNAY JA, ELLIS LM, POLLOCK RE: Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. (2002) 62:203–2042.
   Google Scholar
• JUNG YD, MANSFIELD PF, AKAGI M et al.: Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Ear. J. Cancer (2002) 38:1133–1140.
   PubMed Web of Science ®Google Scholar
• POSEY JA, KHAZAELI MB, DELGROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti-av I33) antibody in patients with metastatic cancer. Cancer Biother: Radiophann. (2001) 16:125–132.
   PubMed Web of Science ®Google Scholar
• GUTHEIL JC, CAMPBELL TN, PIERCE PR et al.: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin avB3. Gin. Cancer Res. (2000) 6:3056–3061.
   Web of Science ®Google Scholar
• TRIKHA M, ZHOU Z, TIMARJ et al.: Multiple roles for platelet GPIIb/IIIa and avI33 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. (2002) 62:2824–2833.
   PubMed Web of Science ®Google Scholar
• EPSTEIN AL, KHAWLI LA, HORNICK JL, TAYLOR CR: Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res. (1995) 55:2673–2680.
   PubMedGoogle Scholar